BMI & ALL: Treatment Outcomes & Efficacy
- Chicago—New research presented at the American Society of Clinical Oncology (ASCO) meeting this month reveals that a high body mass index (BMI) can negatively impact treatment outcomes for...
- One study focused on inotuzumab ozogamicin (InO), a drug used to treat adults with relapsed or refractory B-cell precursor ALL.
- Specifically, at 24 months, the probability of progression-free survival was 19.9% for patients with a healthy BMI, compared to 12.8% for overweight patients and 10.9% for obese patients.
High BMI considerably influences the course of acute lymphoblastic leukemia (ALL) treatment, according too new research presented at the ASCO meeting. The study unveils how a patient’s body mass index plays a crucial role in both treatment efficacy and overall survival rates. Researchers found that patients with higher BMIs experienced lower progression-free survival and overall survival when treated with inotuzumab ozogamicin (InO).Furthermore, global data highlights an increasing burden of disability-adjusted life years (DALYs) linked to high BMI in ALL cases. The findings stress the need for tailored interventions and a comprehensive approach. Discover how body mass index is reshaping ALL treatment efficacy across the globe, brought to you by News Directory 3. Discover what’s next…
Body Mass Index Impacts Acute Lymphoblastic Leukemia treatment
Updated June 19, 2025
Chicago—New research presented at the American Society of Clinical Oncology (ASCO) meeting this month reveals that a high body mass index (BMI) can negatively impact treatment outcomes for acute lymphoblastic leukemia (ALL). The studies examined the role of BMI in both treatment efficacy and overall global trends related to the disease.
One study focused on inotuzumab ozogamicin (InO), a drug used to treat adults with relapsed or refractory B-cell precursor ALL. Researchers, led by William Stock, MD, analyzed data from 338 patients across three previous clinical trials.The findings indicated that while InO’s safety profile remained consistent across different BMI groups, progression-free survival and overall survival rates were lower in patients with higher BMIs.
Specifically, at 24 months, the probability of progression-free survival was 19.9% for patients with a healthy BMI, compared to 12.8% for overweight patients and 10.9% for obese patients. Overall survival probabilities at 24 months followed a similar trend: 28.1% for healthy BMI, 22.1% for overweight BMI, and 17.5% for obese BMI. These results underscore the importance of considering body mass index when assessing treatment strategies for ALL.
Another study, led by Ashish Dixit, MD, investigated global trends in ALL-related deaths and disability-adjusted life years (DALYs) from 1990 to 2021, using data from the Global Burden of Diseases database. The analysis revealed a steady increase in DALYs attributable to high BMI over the 30-year period. While deaths remained relatively stable, the age-standardized mortality ratio gradually increased, suggesting a growing burden of non-fatal impairments and life-years lost due to disability.
“This study demonstrates the escalating burden of high BMI as a risk factor for ALL, primarily driven by a rise in DALYs rather than a proportional increase in mortality,” Dixit said. He emphasized the need for targeted interventions, including preventative measures and improved management strategies, to mitigate the impact of high BMI on ALL.
What’s next
Further research is needed to determine the most effective interventions for managing BMI in ALL patients and improving treatment outcomes. These findings highlight the importance of addressing modifiable risk factors like BMI to enhance survival rates and reduce the overall burden of the disease. The treatment efficacy of ALL could be improved by focusing on preventative measures.